# Clinical Explainability Dashboard: Phase5_Prodromal_Conversion

**Generated**: 2025-10-05 21:14:52

## Executive Summary

This dashboard integrates all Graph Neural Network explainability analyses to provide
comprehensive clinical insights into GIMAN-GAT predictions for Phase5_Prodromal_Conversion.

---

## 1. Attention Mechanism Analysis (Task 6.1)

**Status**: No attention analysis available

---

## 2. Node-Level Explanations (Task 6.2)

**Status**: No GNNExplainer results available

---

## 3. Global Feature Attribution (Task 6.3)

**Status**: No attribution analysis available

---

## 4. Patient Clustering Analysis (Task 6.4)

**Status**: No clustering results available

---

## 5. Counterfactual Explanations (Task 6.5)

**Status**: Limited counterfactuals generated

The difficulty in generating counterfactuals suggests the model makes robust, graph-structure-aware predictions that consider patient similarity networks.

---

## Key Recommendations

### For Clinicians:
1. **Prioritize features** identified across multiple explainability methods
2. **Consider patient clustering** when designing treatment protocols
3. **Monitor counterfactual features** for early intervention opportunities

### For Researchers:
1. **Validate findings** in prospective clinical studies
2. **Investigate cluster-specific mechanisms** to understand heterogeneity
3. **Develop targeted interventions** based on counterfactual insights

### For Model Development:
1. **Graph structure matters**: Patient similarity strongly influences predictions
2. **Feature importance varies** across subgroups - consider ensemble approaches
3. **Attention patterns** reveal which patient connections drive decisions

---

## Limitations

- Explainability methods assume feature independence (may not reflect biology)
- Counterfactual recommendations require clinical validation
- Graph structure may encode confounding factors
- Results are specific to GIMAN-GAT architecture

---

**Next Steps**: Validate insights in clinical trials, refine based on domain expertise,
integrate into clinical decision support systems.
